title: Hypocalcemia induced by raloxifene.
abstract: Raloxifene is an anti-resorptive agent used in postmenopausal osteoporosis. This is the first report of the occurrence of clinically significant hypocalcemia following raloxifene treatment in a patient with occult vitamin D deficiency. Since vitamin D deficiency is widely prevalent in the community, screening for vitamin D deficiency and its correction is advisable before the initiation of anti-resorptive therapy.
authors.affiliation: Endocrinology Department, Austin Health, Victoria, Australia. thuy.vu@austin.org.au
authors.forename: Thuy D T
authors.initials: TD
authors.lastname: Vu
authors.forename: Suresh
authors.initials: S
authors.lastname: Varadarajan
authors.forename: Ego
authors.initials: E
authors.lastname: Seeman
authors.forename: George
authors.initials: G
authors.lastname: Jerums
authors.forename: Richard J
authors.initials: RJ
authors.lastname: MacIsaac
mesh_terms: D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced*; D008403:Mass Screening / Q000379:methods; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D020849:Raloxifene Hydrochloride / Q000009:adverse effects* / Q000627:therapeutic use; D014808:Vitamin D Deficiency / Q000150:complications / Q000175:diagnosis
chemical_list: D050071:Bone Density Conservation Agents; D020849:Raloxifene Hydrochloride